Skip to Content
MilliporeSigma
  • Solid phase microextraction, mass spectrometry and metabolomic approaches for detection of potential urinary cancer biomarkers--a powerful strategy for breast cancer diagnosis.

Solid phase microextraction, mass spectrometry and metabolomic approaches for detection of potential urinary cancer biomarkers--a powerful strategy for breast cancer diagnosis.

Talanta (2012-01-31)
Catarina L Silva, Mário Passos, José S Câmara
ABSTRACT

A sensitive assay to identify volatile organic metabolites (VOMs) as biomarkers that can accurately diagnose the onset of breast cancer using non-invasively collected clinical specimens is ideal for early detection. Therefore the aim of this study was to establish the urinary metabolomic profile of breast cancer patients and healthy individuals (control group) and to explore the VOMs as potential biomarkers in breast cancer diagnosis at early stage. Solid-phase microextraction (SPME) using CAR/PDMS sorbent combined with gas chromatography-mass spectrometry was applied to obtain metabolomic information patterns of 26 breast cancer patients and 21 healthy individuals (controls). A total of seventy-nine VOMs, belonging to distinct chemical classes, were detected and identified in control and breast cancer groups. Ketones and sulfur compounds were the chemical classes with highest contribution for both groups. Results showed that excretion values of 6 VOMs among the total of 79 detected were found to be statistically different (p<0.05). A significant increase in the peak area of (-)-4-carene, 3-heptanone, 1,2,4-trimethylbenzene, 2-methoxythiophene and phenol, in VOMs of cancer patients relatively to controls was observed. Statistically significant lower abundances of dimethyl disulfide were found in cancer patients. Bioanalytical data were submitted to multivariate statistics [principal component analysis (PCA)], in order to visualize clusters of cases and to detect the VOMs that are able to differentiate cancer patients from healthy individuals. Very good discrimination within breast cancer and control groups was achieved. Nevertheless, a deep study using a larger number of patients must be carried out to confirm the results.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
γ-Terpinene, natural, 95%, FG
Sigma-Aldrich
2-Butanone, suitable for HPLC, ≥99.7%
Sigma-Aldrich
2-Butanone, ACS reagent, ≥99.0%
Sigma-Aldrich
2-Butanone, ReagentPlus®, ≥99%
Sigma-Aldrich
2-Heptanone, 99%
Sigma-Aldrich
2-Butanone, ACS reagent, ≥99.0%
Sigma-Aldrich
2-Butanone, JIS special grade, ≥99.0%
Sigma-Aldrich
Phenol, JIS special grade, ≥99.0%
Sigma-Aldrich
Benzoic acid, SAJ first grade, ≥99.5%
Sigma-Aldrich
Phenol, SAJ first grade, ≥98.0%
Sigma-Aldrich
Phenol, ≥99.0%
Sigma-Aldrich
Phenol, ≥99.0%
Sigma-Aldrich
Benzoic acid, SAJ special grade, ≥99.5%
Sigma-Aldrich
2-Butanone, SAJ first grade, ≥99.0%
Supelco
Benzoic acid, Pharmaceutical Secondary Standard; Certified Reference Material
Millipore
Bifido Selective Supplement B, suitable for microbiology
Supelco
Melting point standard 121-123°C, analytical standard
Sigma-Aldrich
Benzoic acid, purified by sublimation, ≥99%
Supelco
Phenol solution, 5000 μg/mL in methanol, certified reference material
Supelco
Phenol solution, certified reference material, 500 μg/mL in methanol
Supelco
Benzoic acid, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
Benzoic acid, natural, ≥99.5%, FCC, FG
Sigma-Aldrich
3-Hexanone, ≥97%
Sigma-Aldrich
(S)-(−)-Limonene, ≥95%, FG
Sigma-Aldrich
Benzoic acid, ReagentPlus®, 99%
Sigma-Aldrich
Dimethyl disulfide, ≥98%, FG
Sigma-Aldrich
Hexanal, 98%
Sigma-Aldrich
2-Butanone, FCC, FG
Supelco
(+)-Carvone, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
Phenol, ACS reagent, ≥99.0%